• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
West Nile Virus Infections - Pipeline Review, H2 2012 Product Image

West Nile Virus Infections - Pipeline Review, H2 2012

  • Published: November 2012
  • 42 pages
  • Global Markets Direct

West Nile Virus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'West Nile Virus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for West Nile Virus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for West Nile Virus Infections. West Nile Virus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for West Nile Virus Infections.
- A review of the West Nile Virus Infections products READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
West Nile Virus Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for West Nile Virus Infections 7
West Nile Virus Infections Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
West Nile Virus Infections Therapeutics – Products under Development by Companies 13
Companies Involved in West Nile Virus Infections Therapeutics Development 14
CEL-SCI Corporation 14
Hemispherx Biopharma, Inc. 15
BioMAS Ltd. 16
MacroGenics, Inc. 17
Kineta, Inc. 18
Hawaii Biotech, Inc. 19
West Nile Virus Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ChimeriVax-West Nile - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Interferon Alfa-n3 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CEL-1000 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 28
HBV-002 West Nile Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AS-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MGAWN-1 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RIG-I Pathway Program - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
VG-WNV - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
West Nile Virus Infections Therapeutics – Drug Profile Updates 37
West Nile Virus Infections Therapeutics - Dormant Products 39
West Nile Virus Infections – Product Development Milestones 40
Featured News & Press Releases 40
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for West Nile Virus Infections, H2 2012 7
Products under Development for West Nile Virus Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
CEL-SCI Corporation, H2 2012 14
Hemispherx Biopharma, Inc., H2 2012 15
BioMAS Ltd., H2 2012 16
MacroGenics, Inc., H2 2012 17
Kineta, Inc., H2 2012 18
Hawaii Biotech, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
West Nile Virus Infections Therapeutics – Drug Profile Updates 37
West Nile Virus Infections Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for West Nile Virus Infections, H2 2012 7
Products under Development for West Nile Virus Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos